今天带你认识拜瑞妥(利伐沙班片)说明书及副作用

Today I will introduce you to the instructions and side effects of (rivaroxaban tablets)

Generic name: Rivaroxaban

Product name: Xarelto

Full names: Rivaroxaban, Xarelto

Indications:

Mainly used to treat venous thrombosis in adults.

Xarelto (rivaroxaban) is indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery.

It is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

How to take:

The recommended dose of Xarelto (rivaroxaban tablets) is 10 mg of Xarelto taken orally, once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

For patients undergoing major hip surgery, the recommended course of treatment is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, patients should take Xarelto immediately and continue taking the dose once daily the next day.

For use in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism:

The recommended dose of Xarelto is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

Xarelto treats DVT (venous thrombosis) and reduces the risk of acute DVT recurrence and PE:

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

Adverse reactions:

The most common adverse reaction of Xarelto (rivaroxaban tablets) is bleeding, which is specifically manifested as hematuria, intracranial hemorrhage, nose bleeding, gum bleeding, gastrointestinal bleeding (blood vomiting, bloody stools), etc.

Other adverse reactions include nausea, abdominal pain, elevated liver enzymes, cholestasis, sinusitis, limb pain, urinary tract infection, etc.

Things to note:

Hepatic Impairment: Avoid use in patients with moderate to severe hepatic impairment (Child-Pugh Class B, C) or liver disease related to coagulation disorders.

Valvular disease: Not recommended for use in patients with prosthetic heart valves or severe rheumatic heart disease. Avoid the use of DOACs (newer anticoagulants) in patients with mechanical valves or moderate to severe mitral stenosis. However, when anticoagulation is required, DOACs can be used in patients with atrial fibrillation and primary aortic valve disease, tricuspid valve disease, or mitral regurgitation.

Drug-Drug Interactions: Significant interactions may exist requiring dose or frequency adjustment, additional monitoring, or the selection of alternative therapies.

Elderly: Use with caution in the elderly. Elderly patients exhibit higher rivaroxaban concentrations compared with younger patients, primarily due to reduced clearance. In general, the efficacy of Xarelto (rivaroxaban tablets) in the elderly (over 65 years old) is similar to that in patients under 65 years old. Both thrombotic and bleeding events were higher in older adults; however, the risk of benefit was favorable in all age groups.

Lactose Intolerance: May contain lactose; not recommended for use in patients with lactose or galactose intolerance (e.g., Lapp lactase deficiency, glucose-galactose malabsorption).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.